• Ep 2- How Are Biosimilars Approved?

  • 2021/12/15
  • 再生時間: 16 分
  • ポッドキャスト

Ep 2- How Are Biosimilars Approved?

  • サマリー

  • Biosimilar medications must still win approval by the U.S. Food and Drug Administration. In this episode, co-hosts Zoe Rothblatt and Conner Mertens explore that approval process, and explain the unique naming convention the FDA came up with for biosimilars.

    “They were really, really driven to understand how their naming convention was being used. And I think that’s pretty admirable, that it’s not just that you’re putting out this standard and saying, ‘This is the standard and you have to follow it'," says Criswell Lavery, Clinical Research Coordinator, University of Pennsylvania

    Among the highlights in this episode:

    2:15 – Getting biosimilars approved – the abbreviated pathway

    3:55 – Why biosimilars have strange names – and why those names have safety implications

    5:37 – Working with the FDA on the approval process

    10:13 – Extrapolation, and how it can potentially bring down costs for patients

    11:59 – What’s ‘interchangeability’ all about?

    14:23 – The FDA approves the first biosimilar as interchangeable

    Contact Our Hosts:

    Zoe Rothblatt, Patient Advocate and Community Outreach Manager at GHLF. zrothblatt@ghlf.org

    Conner Mertens, Patient Advocate and Community Outreach Manager at GHLF. cmertens@ghlf.org

    We’d love to hear what you think. Send your comments to BreakingDownBiosimilars@GHLF.org

    See omnystudio.com/listener for privacy information.

    続きを読む 一部表示
activate_samplebutton_t1

あらすじ・解説

Biosimilar medications must still win approval by the U.S. Food and Drug Administration. In this episode, co-hosts Zoe Rothblatt and Conner Mertens explore that approval process, and explain the unique naming convention the FDA came up with for biosimilars.

“They were really, really driven to understand how their naming convention was being used. And I think that’s pretty admirable, that it’s not just that you’re putting out this standard and saying, ‘This is the standard and you have to follow it'," says Criswell Lavery, Clinical Research Coordinator, University of Pennsylvania

Among the highlights in this episode:

2:15 – Getting biosimilars approved – the abbreviated pathway

3:55 – Why biosimilars have strange names – and why those names have safety implications

5:37 – Working with the FDA on the approval process

10:13 – Extrapolation, and how it can potentially bring down costs for patients

11:59 – What’s ‘interchangeability’ all about?

14:23 – The FDA approves the first biosimilar as interchangeable

Contact Our Hosts:

Zoe Rothblatt, Patient Advocate and Community Outreach Manager at GHLF. zrothblatt@ghlf.org

Conner Mertens, Patient Advocate and Community Outreach Manager at GHLF. cmertens@ghlf.org

We’d love to hear what you think. Send your comments to BreakingDownBiosimilars@GHLF.org

See omnystudio.com/listener for privacy information.

Ep 2- How Are Biosimilars Approved?に寄せられたリスナーの声

カスタマーレビュー:以下のタブを選択することで、他のサイトのレビューをご覧になれます。